Search results
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% After Analyst Downgrade
ETF DAILY NEWS· 11 hours agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 0.2% during mid-day trading on Friday after Citigroup lowered their price target on the stock from $89.00 to $84.00 ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $84.00
ETF DAILY NEWS· 9 hours agoCRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective dropped by investment analysts at Citigroup from $89.00 to $84.00 in a research note issued on ...
Mitsubishi UFJ Asset Management Co. Ltd. Has $218,000 Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
ETF DAILY NEWS· 1 day agoMitsubishi UFJ Asset Management Co. Ltd. lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 22.4% during the fourth quarter, according ...
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 3 days agoWith a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is...
Chutes & Ladders—CRISPR Therapeutics finds new CMO in Sanofi leader
FierceBiotech· 1 day agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
ERS Genomics and IRBM sign CRISPR / Cas9 license agreement
BioPharma-Reporter· 5 days agoCRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The Motley Fool via AOL· 3 days agoLet's check out these two bull market buys to own for the long run. Image source: Getty Images. 1. ...
ARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?
Benzinga via Yahoo Finance· 1 hour agoCathie Wood, co-founder, CEO, and investment manager of the ARK Invest family of exchange-traded...
The Realities And Ethics Of Pig Organ Transplants In Humans : 1A
NPR· 2 days agoWith CRISPR technology, scientists can edit pig genes to be more compatible with a human body, or at...
Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from...
Endpoints News· 1 day ago→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping ...